AXIM Biotechnologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXIM research report →
About the company
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells.
- CEO
- Catalina Valencia
- IPO
- 2014
- Employees
- 6
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $1.36M
- P/E
- -1.31
- P/S
- 0.00
- P/B
- -0.12
- EV/EBITDA
- -33.36
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 9.66%
- ROIC
- 41.24%
- Revenue
- $0 · -100.00%
- Net Income
- $-1,043,083 · 70.30%
- EPS
- $-0.00 · 71.82%
- Op Income
- $-1,319,652
- FCF YoY
- 20.01%
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.15
- Avg Volume
- 167.65K
Get TickerSpark's AI analysis on AXIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 30, 24 | Valencia Catalina | buy | 1,086,216 |
| Mar 15, 24 | HUEMOELLER JOHN WALTER II | other | 250,000 |
| Mar 15, 24 | Valencia Catalina | other | 7,837,500 |
| Mar 15, 24 | Schroeder Blake | other | 35,000 |
| Mar 15, 24 | Cunningham Robert L | other | 35,000 |
| Mar 15, 24 | Scott Timothy Richard | other | 35,000 |
| Mar 15, 24 | O'Rourke Peter | other | 35,000 |
| Mar 15, 24 | MALASEK ROBERT | other | 53,500 |
| Mar 15, 24 | HUEMOELLER JOHN WALTER II | other | 1 |
| May 23, 23 | Phinney Kurt | other | 2,000,000 |
Our AXIM coverage
Recent articles, reports, and earnings notes.
No research on AXIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AXIM report →Similar companies
Peers in the same neighborhood.